
What we're about
Advancing prediction, prevention, and precision therapy for patients with rheumatic diseases
Who we are
Over 200 researchers spanning the basic, clinical, and analytical sciences
How we help
World-class core facilities and investigator support to drive groundbreaking research and launch distinctive careers
Why we care
Patients with rheumatic diseases need better tests and personalized treatments so they can live healthier, longer lives
Recent Publications
- Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity November 28, 2025
- Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment October 6, 2025
- Evaluating Anti-CCL25 as a Therapeutic Strategy to Disrupt Foci Formation in a Spontaneous Murine Model of Sjögren's Disease September 27, 2025
- A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus September 16, 2025
- Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland May 30, 2025
- A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease May 4, 2025
- Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis March 17, 2025


